3 news items
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
GLPG
4 Apr 24
-label, multi-center studies designed to assess the safety, efficacy and feasibility of point-of-care manufactured GLPG5101 and GLPG5201 in patients
Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst
GILD
GLPG
1 Apr 24
-stage trials to assess its autologous cell therapy (CAR-T) treatments for hematologic cancers.
The unique selling points of Galapagos
Galapagos announces full year 2023 results and outlook for 2024
GLPG
22 Feb 24
of the Pharmaceutical Risk Assessment Committee (PRAC) to add safety measures for the JAK inhibitors class of medicines
- Prev
- 1
- Next